Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
WASHINGTON, DC, Jan. 6, 2016 (GLOBE NEWSWIRE) -- The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected David Simmons, Chairman and CEO of PPD, as its 2016 Chairman, and John Hubbard, President and CEO of Bioclinica, as Vice Chairman.
"ACRO plays a vital role in promoting the interests of the CRO industry globally," said Simmons. "Not only does ACRO represent the industry on legislative and regulatory matters but, increasingly, the association helps build relationships with the sponsor, research site, investigator and patient communities. I look forward to leading the organization in 2016 as we pursue a focused and productive agenda."
|
|||||
Simmons added that, in addition to its legislative and regulatory priorities, ACRO is exploring further ways to benefit the industry in areas such as patient recruitment, workforce development and clinical trial efficiency.
"ACRO successfully advanced CRO industry interests in 2015 by influencing health and tax policy in the United States and navigating the implementation of the Clinical Trial Regulation in the European Union," said ACRO Executive Director Doug Peddicord, Ph.D. "We will build on our successes this year and continue to promote our industry through our robust communications and advocacy programs."
ACRO also elected as officers: Judd Hartman, General Counsel of PPD, as Treasurer; and Maria Kraus, Executive Vice President of Corporate Development and Strategy at Bioclinica, as Secretary.
About ACRO
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. The Association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 110,000 professionals worldwide and conduct research in 142 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. RebelMouse.
A photo accompanying this release is available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=38345
CONTACT: John Lewis
[email protected]
202-464-9340
